RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial called TETRANITE® to immediately stabilize and fixate cranial flaps following craniotomy procedures associated with brain surgery.
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody and have demonstrated
The ransomware group AlphV/BlackCat has claimed responsibility for the data breach and a second incident involving the company.
Henry Schein says 29K people affected in September cyber incident Read More »
The inquiry comes as the White House this week said it would investigate private equity investment in healthcare as federal scrutiny of firms ramps up.
Senators probe private equity’s role in hospital operations Read More »
As Vertex and CRISPR Therapeutics’ exa-cel and Verve Therapeutics’ VERVE-101 move forward, questions remain about possible drawbacks of such therapies.
FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential Risks Read More »
Edwards is the latest healthcare firm to spin off a business to focus on specific markets, following larger companies like Johnson & Johnson and GE.
The American Hospital Association and the Federation of American Hospitals sent letters to Congress this week opposing a bill that would equalize payments for drugs administered in outpatient clinics.
Hospital lobbies push back on site-neutral provision in House bill Read More »
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.
IDEAYA Biosciences, Inc. today announced that, on November 30, 2023 , the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company’s common stock to a newly hired employee.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More »
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023.
